The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2022 | Novel targets in 2022
In this discussion, the experts discuss IMiD resistance, immunogenic cell death, novel approaches to amyloidosis, as well as approaching a cure. Faith Davies, MBBCh, MRCP, MD, FRCPath, of NYU Langone Medical Center, New York, NY, chairs this session with Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK and Hearn Jay Cho, MD, PhD, of Mount Sinai Hospital, New York, NY. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
